• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Pristiq (desvenlafaxine extended-release) tablet

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – February 2010


Summary View



Adverse Reactions Reported With Other SNRIs 
  • Although the following are not considered adverse reactions for desvenlafaxine succinate, they are adverse reactions for other SNRIs and may also occur with desvenlafaxine succinate: gastrointestinal bleeding, hallucinations, and photosensitivity reactions.